Curaleaf Goes Hostile In $270 Million Bid For Aurora

Curaleaf Goes Hostile In $270 Million Bid For Aurora

Jeremy Berke

Tue, August 11, 2026 at 11:20 PM GMT+3 3 min read

• CURLF -0.04%

THE GIST

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

U.S. cannabis firm Curaleaf plans to launch a hostile takeover bid of Canadian counterpart Aurora, after Curaleaf says "repeated attempts" to engage Aurora CEO Miguel Martin were left on read. The deal makes sense on paper, but actually getting it over the finish line is another story.

WHAT HAPPENED

Curaleaf sent two letters, the first dated June 23, with a formal letter of intent outlining the rationale. They said they sent a follow-up on July 7, which also received no response. So now they're going over the board's head and asking shareholders directly.

"Our proposed acquisition of Aurora would create the largest cannabis platform in the world and cements our global leadership position," Curaleaf CEO and Chairman Boris Jordan said on X. Aurora didn't immediately comment on the deal.

The deal would see Curaleaf acquire Aurora for $4 per share, implying a 45% premium on the 30-day average of Aurora's share price. The deal works out to roughly $270 million on a fully diluted basis.

Aurora's TSX-listed shares surged about 21% on the news, indicating that long-suffering shareholders like the idea. The company, one of the earliest publicly traded Canadian cannabis operators, is down more than 99% from its all-time high of over $1,200 per share in 2018, when Canada became the first large economy to federally legalize cannabis. Curaleaf shares are up about 5% as of Tuesday afternoon.

Curaleaf says it expects the combined company to generate $1.5 billion in annual revenue.

WHY IT MATTERS

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

The deal makes sense on paper: It's all about global distribution, which is becoming a highly lucrative segment for the better-performing operators.

Canadian producers can ship raw cannabis into Europe's lucrative medical markets because Canada legalized federally and its regulations are stable. American operators can't. Cannabis is still federally illegal in the U.S., so product grown in Arizona or New Jersey can't legally cross a border. That's why Curaleaf's international arm grows in Portugal, Spain, and Canada rather than exporting from its U.S. footprint. It also explains the bid. Aurora comes with more than 50 tons of EU-certified annual capacity that Curaleaf would otherwise have to build or buy piecemeal.

Aurora's international exports surged 17% year-over-year, per its first-quarter print, supplying Germany, Poland, and the United Kingdom. Europe is where cannabis growth lives right now, and Curaleaf's international arm needs supply. In exchange, Aurora shareholders would get exposure to the $32 billion U.S. market right as federal rescheduling, if finalized, supercharges the industry's economics.

Look at Aurora's Canadian competitor Village Farms, which saw its second-quarter exports grow 73% year-over-year. And Organigram, another large Canadian cannabis producer, acquired Sanity Group, a German medical cannabis firm, in a deal valued at up to approximately $289 million earlier this year.

The bigger picture is that U.S. cannabis operators, buoyed by rescheduling hopes, now have expensive enough stock to go shopping in Canada, where the sector has spent five years in the discount bin. Curaleaf is the first to actually pull the trigger on a hostile deal. If it works, it won't be the last. Still, despite the brewing tailwinds, U.S. cannabis is still in a bear market: The AdvisorShares Pure U.S. Cannabis ETF (MSOS), of which Curaleaf is a large holding, has lost about 80% since inception in 2020, making Curaleaf paper a particularly risky proposition, but cannabis investors are, of course, used to risk.

WHAT'S NEXT

Hostile bids fail all the time, and the market knows it. Aurora's stock popped on the news but still trades well below what the offer's worth, a gap that's Wall Street's way of pricing the deal as roughly a coin flip. Aurora's board has already said no twice, and the formal offer hasn't even launched. Once it does, shareholders get 105 days to decide.

Either way, expect there to be some fireworks.